Rate of Cancer During Pregnancy Lower Than Expected
the Cancer Therapy Advisor take:
The number of observed cancer cases during pregnancy was lower than predicted for all types, according to an article published online in the journal Cancer.
The study was register-based and used data from the Swedish Multi-Generation Register and the National Cancer Register from 1963 to 2007. The women were assessed at seven time periods: pregnancy, the three trimesters, 0-6 months, 7-12 months, and 2 years postpartum.
In the study, pregnancy-associated cancer (PAC) was determined to be a malignancy detected during pregnancy or within 2 years postpartum.
Results showed that the most common PACs were melanoma (n = 232), breast cancer (n = 139) and cervical cancer (n = 139).
The overall number of cancer cases during pregnancy was lower than expected by the study for all types of cancer, with the observed versus the expected (O/E) ratio of 0.46 (95% CI: 0.43, 0.49).
Throughout the windows of 0-6 months, 7-12 months, and the second year after delivery, the O/E ratio was close to 1 (0.93; 95% CI: 0.88, 0.98; 0.96; 95% CI: 0.91, 1.01; and 0.95; 95% CI: 0.92, 0.99, respectively).
All sites had a lower than expected rate of PAC, which could not be completely explained by delayed diagnosis. A rebound in the number of cancer cases after pregnancy was limited to melanoma, nervous system malignancies, breast cancer, and thyroid cancer.
The number of observed cancer cases during pregnancy was lower than predicted for all types.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- St John's Wort and Cancer
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC
- Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation
- Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC
- Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC